Wisconsin Alumni Research Foundation

Katarzyna Sokolowska

Hector Floyd Deluca

Lori A Plum

Margaret Clagett-Dame

Rafal R Sicinski

Agnieszka Glebocka

Antonio Mouriño

This invention discloses 6-methylvitamin Danalogs, and specifically 1&#x3b1;,25-dihydroxy-6-methylvitamin D, and pharmaceutical uses therefor. This compound exhibits vitamin D receptor binding activity and transcription activity as well as activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent, especially for the treatment or prevention of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. This compound also exhibits low in vivo calcemic activity, but because it binds the receptor with the same affinity as the native hormone calcitriol, it may act as an antagonist to inhibit development of hypercalcemia.

[object Object]

19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 1&#x3b1;-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, secondary hyperparathyroidism, psoriasis, or other skin diseases.

19-nor-vitamin D analogs with 1,2-dihydrofuran ring

19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3&#x3b2;-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases.

Growing community of inventors

Lomza, Poland

Katarzyna Sokolowska